Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTB-3550 in High Risk CD33+ Hematologic Malignancies
NCT03214666Phase 2Terminated
- Sponsor
- GT Biopharma, Inc.
- Start
- Jan 2020
- Primary completion
- Aug 2021
- Modality
- Antibody Fragments, Prophylactic Vaccines, Interleukins
- Countries
- 1
01
Overview
A Phase 2 trial of GTB-3550 TriKE in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), systemic mastocytosis (SM), sponsored by GT Biopharma, Inc.. Started Jan 2020; status: terminated.
02
Drugs
GTB-3550 TriKE
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)systemic mastocytosis (SM)
Beyond the preview
Go deeper on NCT03214666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03214666.